Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

51.29 -0.18 (-0.35%)
Streaming Delayed Price Updated: 2:28 PM EST, Dec 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,021,300
Open 51.52
Bid (Size) 51.28 (700)
Ask (Size) 51.29 (500)
Prev. Close 51.47
Today's Range 51.06 - 51.67
52wk Range 43.08 - 93.80
Shares Outstanding N/A
Dividend Yield 4.29%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why Novo Nordisk Stock Dropped on Monday ↗
The cost of Wegovy is about to decrease significantly in a populous overseas market. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three... 
Via MarketMinute
Topics ETFs Economy World Trade

Performance

YTD
-41.4%
-41.4%
1 Month
+5.9%
+5.9%
3 Month
-7.6%
-7.6%
6 Month
-25.7%
-25.7%
1 Year
-40.2%
-40.2%

More News

Read More
News headline image
The 2026 Horizon: Wall Street Bets on the 'Application Era' and the Nuclear Renaissance
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
The Trillion-Dollar Apothecary: Inside Eli Lilly’s Era of Metabolic Dominance
Via PredictStreet
Topics Earnings Economy Intellectual Property
News headline image
Market Breather: Benchmarks Pause Record-Breaking Year as Volatility Signals Year-End Reset
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
This Beaten-Down Stock Just Jumped By 8%. Time to Buy? ↗
Via The Motley Fool
News headline image
Novo Nordisk Slashes Weight Loss Drug Price By Up To 50% In China: Report ↗
Via Stocktwits
Topics Intellectual Property
News headline image
The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA. ↗
Via The Motley Fool
News headline image
3 Drug Stocks to Buy at a Discount ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Should You Invest in Ozempic Maker Novo Nordisk in 2026? ↗
Via The Motley Fool
News headline image
Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026 ↗
Via MarketBeat
News headline image
This Smallcap Pharma Stock Is Gaining Retail Buzz Ahead Of A Key FDA Ruling ↗
Via Stocktwits
News headline image
Buying This Pharmaceutical Stock Could Make You a Millionaire Retiree ↗
Via The Motley Fool
News headline image
Betting on the 'Santa Squeeze': Unusual Options Activity Surges as 2025 Draws to a Close
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle? ↗
Via The Motley Fool
News headline image
Pfizer’s 2026 Outlook Misses the Mark as Post-Pandemic Hangover and Patent Cliff Loom
Via MarketMinute
Topics Economy Intellectual Property
News headline image
The Oral Revolution: Novo Nordisk’s High-Stakes Bet on the Wegovy Pill
Via PredictStreet
Topics Economy Intellectual Property World Trade
News headline image
The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era
Via PredictStreet
Topics Economy Government Intellectual Property
News headline image
The Weight of Innovation: Eli Lilly’s Dominance in the GLP-1 Era
Via PredictStreet
Topics Economy
News headline image
Novo Nordisk (NVO) Research: The Oral Wegovy Pivot and the 2026 Outlook
Via PredictStreet
Topics Economy Intellectual Property
News headline image
Hims & Hers Hit A GLP-1 Speed Bump This Year — But Growth Is Just Cooling, Not Cracking ↗
Via Stocktwits
News headline image
Novo Nordisk A/S-Spons ADR (NYSE:NVO): A Prime Candidate for Steady Dividend Income ↗
Via Chartmill
News headline image
Stock Market Today, Dec. 23: U.S. Stocks Hold Near Records on Narrow Tech-Led Gains ↗
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
Why Novo Nordisk Stock Popped Today ↗
Via The Motley Fool

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 51.29
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 12/30/25 02:28 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.